JP2022533538A5 - - Google Patents
Info
- Publication number
- JP2022533538A5 JP2022533538A5 JP2021565723A JP2021565723A JP2022533538A5 JP 2022533538 A5 JP2022533538 A5 JP 2022533538A5 JP 2021565723 A JP2021565723 A JP 2021565723A JP 2021565723 A JP2021565723 A JP 2021565723A JP 2022533538 A5 JP2022533538 A5 JP 2022533538A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antigen
- bispecific antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024131038A JP2024170410A (ja) | 2019-05-08 | 2024-08-07 | T細胞媒介性免疫を調節するための材料及び方法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962844976P | 2019-05-08 | 2019-05-08 | |
| US201962844966P | 2019-05-08 | 2019-05-08 | |
| US201962844959P | 2019-05-08 | 2019-05-08 | |
| US201962844995P | 2019-05-08 | 2019-05-08 | |
| US201962844970P | 2019-05-08 | 2019-05-08 | |
| US62/844,959 | 2019-05-08 | ||
| US62/844,966 | 2019-05-08 | ||
| US62/844,970 | 2019-05-08 | ||
| US62/844,976 | 2019-05-08 | ||
| US62/844,995 | 2019-05-08 | ||
| PCT/US2020/031749 WO2020227457A1 (en) | 2019-05-08 | 2020-05-07 | Materials and methods for modulating t cell mediated immunity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131038A Division JP2024170410A (ja) | 2019-05-08 | 2024-08-07 | T細胞媒介性免疫を調節するための材料及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022533538A JP2022533538A (ja) | 2022-07-25 |
| JP2022533538A5 true JP2022533538A5 (cg-RX-API-DMAC7.html) | 2023-05-16 |
| JP7686571B2 JP7686571B2 (ja) | 2025-06-02 |
Family
ID=73051172
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021565723A Active JP7686571B2 (ja) | 2019-05-08 | 2020-05-07 | T細胞媒介性免疫を調節するための材料及び方法 |
| JP2024131038A Pending JP2024170410A (ja) | 2019-05-08 | 2024-08-07 | T細胞媒介性免疫を調節するための材料及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024131038A Pending JP2024170410A (ja) | 2019-05-08 | 2024-08-07 | T細胞媒介性免疫を調節するための材料及び方法 |
Country Status (22)
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| MX386714B (es) | 2015-01-27 | 2025-03-11 | Lava Therapeutics N V | Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d). |
| JP7457007B2 (ja) | 2018-09-19 | 2024-03-27 | ラヴァ・セラピューティクス・エヌ・ヴイ | 二重作用CD1d免疫グロブリン |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク,インコーポレーテツド | T細胞媒介性免疫を調節するための材料及び方法 |
| JP2022545196A (ja) * | 2019-08-16 | 2022-10-26 | ガンマデルタ セラピューティクス リミテッド | 抗tcrデルタ可変1抗体の治療的使用 |
| CA3173268A1 (en) * | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) * | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| CN116323667A (zh) | 2020-07-08 | 2023-06-23 | 拉法医疗股份有限公司 | 结合PSMA和γ-δT细胞受体的抗体 |
| US12076413B2 (en) | 2020-10-28 | 2024-09-03 | Janssen Biotech, Inc. | Compositions and methods for modulating delta gamma chain mediated immunity |
| CA3211114A1 (en) * | 2021-02-16 | 2022-08-25 | Janssen Biotech, Inc. | Materials and methods for enhanced linker targeting |
| WO2022180271A1 (en) | 2021-02-26 | 2022-09-01 | LAVA Therapeutics N.V. | Antibodies that bind CD123 and gamma-delta T cell receptors |
| JP2026526851A (ja) * | 2023-07-26 | 2026-08-10 | ヤンセン バイオテツク,インコーポレーテツド | 細胞増殖のための材料及び方法 |
| AU2024379650A1 (en) * | 2023-11-15 | 2026-06-04 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Trgv9 binding proteins and medical use thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2698880B1 (fr) | 1992-11-25 | 1995-02-24 | Inst Nat Sante Rech Med | Procédé de production de récepteurs T solubles, produits ainsi obtenus et leur utilisation dans des compositions diagnostiques ou thérapeutiques. |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| AU2002351208A1 (en) | 2001-12-03 | 2003-06-17 | Abgenix, Inc. | Antibodies against carbonic anhydrase IX (CA IX) tumor antigen |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP2012505654A (ja) | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク,インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| JP5996429B2 (ja) | 2009-09-03 | 2016-09-21 | ジェネンテック, インコーポレイテッド | 関節リウマチの治療、診断及びモニターするための方法 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2012018767A2 (en) | 2010-08-05 | 2012-02-09 | Anaptysbio, Inc. | Antibodies directed against il-17 |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| LT2748201T (lt) * | 2011-08-23 | 2018-02-26 | Roche Glycart Ag | Dvigubai specifinė t ląsteles aktyvinantį antigeną surišanti molekulė |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| CN104203981A (zh) | 2011-12-19 | 2014-12-10 | 合成免疫股份有限公司 | 双特异性抗体分子 |
| US9907820B2 (en) * | 2013-10-25 | 2018-03-06 | Board Of Regents, The University Of Texas System | Polyclonal gamma delta T cells for immunotherapy |
| US10501540B2 (en) | 2014-04-10 | 2019-12-10 | Lava Therapeutics B.V. | Immunoglobulins binding human Vγ9 Vδ2 T cell receptors |
| DK3189081T3 (da) | 2014-09-05 | 2020-05-04 | Janssen Pharmaceutica Nv | Cd123-bindende midler og anvendelser deraf |
| RU2756247C2 (ru) | 2014-11-17 | 2021-09-28 | Эдисет Био, Инк. | Генетически модифицированные гамма дельта т-клетки |
| DK3303394T3 (da) | 2015-05-29 | 2020-07-06 | Agenus Inc | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf |
| EP3560955A4 (en) | 2016-12-26 | 2020-12-23 | Kyowa Kirin Co., Ltd. | ANTIBODIES CAPABLE OF BINDING TO MYELIN OLIGODENDROCYTE GLYCOPROTEIN |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| WO2019147735A1 (en) * | 2018-01-23 | 2019-08-01 | New York University | Antibodies specific to delta 1 chain of t cell receptor |
| JOP20190116A1 (ar) | 2018-05-24 | 2019-11-24 | Janssen Biotech Inc | الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها |
| BR112020023508A2 (pt) | 2018-05-24 | 2021-03-30 | Janssen Biotech, Inc. | Anticorpos anti-cd3 e usos dos mesmos |
| JP7686571B2 (ja) | 2019-05-08 | 2025-06-02 | ヤンセン バイオテツク,インコーポレーテツド | T細胞媒介性免疫を調節するための材料及び方法 |
| CA3173268A1 (en) | 2020-02-27 | 2021-09-02 | Janssen Biotech, Inc. | Materials and methods for modulating an immune response |
| US20210284731A1 (en) | 2020-03-13 | 2021-09-16 | Janssen Biotech, Inc. | Methods and materials for modulating an immune response |
| PE20231517A1 (es) | 2020-03-13 | 2023-09-28 | Janssen Biotech Inc | Materiales y metodos para la union de siglec-3/cd33 |
| US12076413B2 (en) | 2020-10-28 | 2024-09-03 | Janssen Biotech, Inc. | Compositions and methods for modulating delta gamma chain mediated immunity |
-
2020
- 2020-05-07 JP JP2021565723A patent/JP7686571B2/ja active Active
- 2020-05-07 PH PH1/2021/552790A patent/PH12021552790A1/en unknown
- 2020-05-07 MA MA055903A patent/MA55903A/fr unknown
- 2020-05-07 KR KR1020217036132A patent/KR20220017892A/ko not_active Ceased
- 2020-05-07 CN CN202080043002.2A patent/CN113966231B/zh active Active
- 2020-05-07 CR CR20210548A patent/CR20210548A/es unknown
- 2020-05-07 TW TW109115171A patent/TW202108618A/zh unknown
- 2020-05-07 BR BR112021022089A patent/BR112021022089A2/pt not_active IP Right Cessation
- 2020-05-07 EP EP20801607.1A patent/EP3965818A4/en active Pending
- 2020-05-07 WO PCT/US2020/031749 patent/WO2020227457A1/en not_active Ceased
- 2020-05-07 PE PE2021001851A patent/PE20220763A1/es unknown
- 2020-05-07 US US16/869,401 patent/US11667712B2/en active Active
- 2020-05-07 SG SG11202112021QA patent/SG11202112021QA/en unknown
- 2020-05-07 AU AU2020267504A patent/AU2020267504A1/en not_active Abandoned
- 2020-05-07 CA CA3139508A patent/CA3139508A1/en active Pending
- 2020-05-07 MX MX2021013532A patent/MX2021013532A/es unknown
-
2021
- 2021-11-02 JO JOP/2021/0297A patent/JOP20210297A1/ar unknown
- 2021-11-03 IL IL287817A patent/IL287817A/en unknown
- 2021-11-04 DO DO2021000229A patent/DOP2021000229A/es unknown
- 2021-11-04 CL CL2021002905A patent/CL2021002905A1/es unknown
- 2021-11-26 CO CONC2021/0015998A patent/CO2021015998A2/es unknown
- 2021-12-03 EC ECSENADI202187921A patent/ECSP21087921A/es unknown
-
2023
- 2023-04-25 US US18/306,401 patent/US12673995B2/en active Active
-
2024
- 2024-08-07 JP JP2024131038A patent/JP2024170410A/ja active Pending